Yunus Kasim Terzi

Prof. Dr. Yunus Kasim Terzi

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
YSYuanbin Song
Yuanbin Song
ARAnthony Rongvaux
Anthony Rongvaux
ATAshley Taylor
Ashley Taylor
TJTingting Jiang
Tingting Jiang
TTToma Tebaldi
Toma Tebaldi
SHStephanie Halene
Stephanie Halene
Comprehensive preclinical studies of Myelodysplastic Syndromes (MDS) have been elusive due to limited ability of MDS stem cells to engraft current immunodeficient murine hosts. Here we report a MDS patient-derived xenotransplantation model in cytokine-humanized immunodeficient “MISTRG” mice that provides efficient and faithful disease representation across all MDS subtypes. MISTRG MDS patient-derived xenografts (PDX) reproduce patients’ dysplastic morphology with multi-lineage representation, including erythro- and megakaryopoiesis. MISTRG MDS-PDX replicate the original sample’s genetic complexity and can be propagated via serial transplantation. MISTRG MDS-PDX demonstrate the cytotoxic and differentiation potential of targeted therapeutics providing superior readouts of drug mechanism of action and therapeutic efficacy. Physiologic humanization of the hematopoietic stem cell niche proves critical to MDS stem cell propagation and function in vivo. The MISTRG MDS-PDX model opens novel avenues of research and long-awaited opportunities in MDS research.

15 July 2014 in Pharmaceutical Biology
Verified
Journal Article
Closed access
PDF file
ÖIÖzlem Darcansoy İşEri
Özlem Darcansoy İşEri
FSFeride Iffet Sahin
Feride Iffet Sahin
YTYunus Kasim Terzi
Yunus Kasim Terzi
EYErkan Yurtcu
Erkan Yurtcu
SES. Remzi Erdem
S. Remzi Erdem
FSFaik Sarialioglu
Faik Sarialioglu
Context: Propranolol, atenolol, and ICI118,551 are non-selective β-adrenergic receptor (AR), β1-AR, and β2-AR antagonists, respectively. Objective: We investigated the efficacy of propranolol, atenolol, and ICI118,551 on proliferation, migration, and invasion of non-stimulated breast (MCF7), colon (HT-29), and hepatocellular (HepG2) cancer cells. Materials and methods: β-AR expression profiling of cells was performed by real time PCR. Cell proliferation was determined by MTT. Boyden chamber and scratch assays were performed to evaluate invasion and migration. Results and discussion: All cell lines expressed β-ARs. ICI118,551 was the most cytotoxic, whereas atenolol was the least effective β-AR antagonist for 24, 48, and 72 h. Cell invasion was inhibited by ICI118,551 (45, 46, and 50% for MCF7, HT29, and HepG2, respectively) and propranolol (72, 65, and 90% for MCF7, HT29, and HepG2, respectively). Propranolol, atenolol, and ICI118,551 reduced migration of MCF7, HT-29, and HepG2 cells to varying extents depending on the application concentration and duration. Propranolol and atenolol reduced migration of MCF7 and HT-29 in a concentration-dependent manner, whereas migration of these cells decreased after 48 and 72 h of ICI118,551 applications. Conclusion: Beta2-AR antagonist seemed to be the most cytotoxic β-blocker on non-stimulated cancer cells. Propranolol and ICI118,551 were more effective than atenolol in inhibiting invasion and migration of non-stimulated MCF7 and HT-29 cells; ICI118,551 being the most potent. Concordantly, β2-selective blockage seemed to be more effective for non-stimulated cells. Effect of the selective β-AR antagonists showed variation depending on the concentration, incubation time, and histological origin of cells.

15 January 2006 in Cancer Genetics and Cytogenetics
Verified
Journal Article
Closed access
PDF file
SOSibel Oguzkan
Sibel Oguzkan
YTYunus Kasim Terzi
Yunus Kasim Terzi
EGElif Güler
Elif Güler
MDMurat Derbent
Murat Derbent
PAPınar Isık Agras
Pınar Isık Agras
SASukriye Ayter
Sukriye Ayter

16 June 2014 in Journal of the Turkish-German Gynecological Association
Verified
Journal Article
Closed access
NYNafiye Yilmaz
Nafiye Yilmaz
GOGulnur Ozaksit
Gulnur Ozaksit
YTYunus Kasim Terzi
Yunus Kasim Terzi
SYSaynur Yilmaz
Saynur Yilmaz
BBBurcu Budak
Burcu Budak
FSFeride Iffet Sahin
Feride Iffet Sahin
Pelvic organ prolapse (POP) is a common disorder that negatively impacts the quality of life in many women. Uterosacral ligaments (USLs) are supportive structures of the pelvic organs that are often attenuated in women with POP. The HOXA genes regulate the development of the uterosacral ligaments. We compared expression of HOXA11 and MMP2 in USLs of women with and without POP. A prospective sequential cross sectional study was conducted in ZTB Women's Health Research and Education Hospital. We compared expression of HOXA11 and MMP2 in USLs of women with (n:18) and without (n: 15) POP. Total RNA was isolated from patient (n:18) and control (n:15) uterosacral ligament tissues with TriPure isolation reagent according to the manufacturer's instructions. Expression levels of HOXA11 and MMP2 were determined using semiquantitative RT-PCR in a Light Cycler 480 system. Real-time ready catalog assays, which are short FAM-labeled hydrolysis probes containing locked nucleic acid, were used for RT-PCR reactions. There was no difference in patients' mean age, parity, body mass indexes, and menopausal status between two groups. Means of RNA expression of MMP2 were 1.27±0.6 and 0.75±0.4 in the POP group vs control group, respectively (p:0.007). Means of RNA expression of HOXA 11 were 2.57±2.4 and 1.94±1.4 in the POP group vs control group, respectively (p:0.376). The POP group was divided as mild and severe POP; there was no difference in HOXA11 and MMP2 RNA expression between groups (p>0.05). Although there was no difference HOXA11 RNA expression in USLs with the POP group vs control, there was a significant difference MMP2 RNA expression in USLs with the POP group vs control. There are limited studies on this subject, and study results are contradictory. Further investigations with larger numbers of cases are needed to clarify this subject.

1 May 2014 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
LOLale Olcay
Lale Olcay
THTuncay Hazirolan
Tuncay Hazirolan
YYYildiz Yildirmak
Yildiz Yildirmak
EEEsra Erdemli
Esra Erdemli
YTYunus Kasim Terzi
Yunus Kasim Terzi
CBCeylan Bal
Ceylan Bal
Iron overload in hereditary hemochromatosis and hematologic malignancy has unfavorable effects on morbidity. Herein, 53 children (age 108.4±58.3 mo, 25 girls and 28 boys) with acute myeloblastic and lymphoblastic leukemia, who received 4 different chemotherapy protocols, were evaluated for iron overload throughout chemotherapy. Iron overload arose: (1) before chemotherapy, which was dependent on neither chemotherapy nor packed red blood cell transfusions and (2) after chemotherapy, which was dependent on the duration and nature of chemotherapy and partially on transfusion of packed red blood cells. Iron overload was documented in 75% of patients with a ferritin level >1000 ng/mL, by liver and heart magnetic resonance imaging, and they were administered iron-chelation therapy with success. Three of 10 radiologically iron-overloaded patients were heterozygous for H63D mutation. Aminolevulinic acid and porphobilinogen levels were normal. Light microscopic examination of the bone marrow revealed increased iron granules in erythroblasts, platelets, and megakaryocytes, iron-laden macrophages, free iron in the matrix, dyshematopoiesis, and apoptotic cells. Electron microscopic examination revealed iron-laden secondary lysosomes and autolysosomes in normoblasts and iron-laden primary granules in promyelocytes, irrelevant to the ferritin level, implying autophagia due to chemotherapy as a source of the excess iron. We think that iron overload, which is an important complication of acute leukemia, should be evaluated separately from “transfusion overload,” and the management principles specific to leukemia should be implemented.

9 June 2016 in Journal of the Turkish-German Gynecological Association
Verified
Journal Article
Closed access
NYNafiye Karakas Yilmaz
Nafiye Karakas Yilmaz
PKPeren Hatice Karagin
Peren Hatice Karagin
YTYunus Kasim Terzi
Yunus Kasim Terzi
IKInci Kahyaoglu
Inci Kahyaoglu
SYSaynur Yilmaz
Saynur Yilmaz
FSFeride Iffet Sahin
Feride Iffet Sahin
Objective: Although the association between BRCA1 and BRCA2 gene mutations and breast and ovarian cancer is known, there is insufficient data about premature ovarian insufficiency (POI). However, several studies have reported that there might be a relationship between POI and BRCA1 and BRCA2 gene mutation. Therefore, in the present study, we aimed to investigate the role of BRCA1 and BRCA2 gene mutations in the etiology of POI in a Turkish population. Material and Methods: The cohort was classified into two groups: a study group, consisting of 56 individuals diagnosed with premature ovarian insufficiency (and who were younger than 40 years of age, had an antral follicle count 12 IU/I), and a control group, consisting of 45 fertile individuals. A total of 101 individuals were analyzed by next-generation sequencing to detect BRCA1 and BRCA2 gene mutations. Results: We detected four new variations (p.T1246N and p.R1835Q in BRCA1 and p.I3312V and IVS-7T>A in BRCA2) that had not been reported before. Conclusion: We did not find an association between the BRCA1 and BRCA2 gene mutations and premature ovarian insufficiency. However, larger, functional studies are needed to clarify the association.